2008
2007
- 19
December 2007 - Altus Pharmaceuticals Reacquires ALTU-238 Global Development and Commercialzation Rights
- 10
December 2007 - Eisai Agrees to Buy MGI
Pharma for $3.9 Billion
- 3
December 2007 - Santarus Licenses Rights to GlaxoSmithKline for ZEGERID Immediate-Release Omeprazole Products in over 100 Countries
- 2
December 2007 - MorphoSys and Novartis Forge New Strategic
Alliance to Establish Innovative Therapeutic Antibody Pipeline
- One of the Industry's Largest Pharma-Biotech R&D Collaborations
- 19
November 2007 - Olympus and Gyrus are pleased to announce today of the acquisition by Olympus
- 6
November 2007 - Momenta Pharmaceuticals Announces Receipt of FDA Letter -- M-Enoxaparin ANDA Not Approvable in Current Form
- 6
November 2007 - GTx, Inc. and Merck & Co., Inc. Enter Global Strategic Collaboration for the Development of SARMs, a Novel Investigational Class of Drugs to Treat Muscle Loss and other Musculoskeletal Conditions
- 1
November 2007 - Allergy Therapeutics - Update on FDA Clinical
Hold
- 1
November 2007 -
Shire – Further upgrade to 2007 financial guidance based on strong revenue growth; VYVANSE™ demand on track
- 30
October 2007 - Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
- 30
October 2007
- Onyx - Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- 29
October 2007 - Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
- 25
October 2007 - Celgene Reports Record Third Quarter Product Sales and Operating Profits
- 24
October 2007 - BTG licensee Tolerx forms collaboration with
GlaxoSmithKline to develop and commercialise TRX4
- 23
October 2007
- Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
- 23
October 2007
- Noven - FDA issues approvable letter for STAVZOR™ delayed release Valproic acid capsules
- 22
October 2007
- OSI Pharmaceuticals - Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
- 22
October 2007
- ProStrakan to Establish US Sales Force through Strategic Alliance with NovaQuest
- 17
October 2007
- Shire - FDA advisory committee votes in favor of earlier use of phosphate binders in stage 4 kidney disease patients with Hyperphosphatemia
- 15
October 2007
- Pharmacopeia Acquires Selective Androgen Receptor Modulator ("SARM") Program from Bristol-Myers Squibb
- 15
October 2007
- Achillion Reports Safety and Potent Antiviral Activity in
Topline Results From Elvucitabine Phase 2 Study in HIV-Infected
Patients
- 15
October 2007 - Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study
- 11
October 2007
- Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
- 10
October 2007
- Optos Confirms European Expansion
- 8
October 2007
- Noven announces results of Phase 3 clinical study for once-daily Lithium product
- 3
October 2007
- Acusphere Provides Update on Progress toward NDA Filing for Imagify(TM)
- 1
October 2007
- CSL - U.S. Food & Drug Administration approves CSL influenza virus vaccine, for marketing in the U.S.
- 28
September 2007
- ProStrakan - Regulatory Update
- 26
September 2007
- Affibody to Start Clinical Development of a New Approach for the Diagnosis of Cancer
- 24
September 2007
- Sonus - Phase 3 Pivotal Trial of TOCOSOL® Paclitaxel Does Not Meet Primary Endpoint
- 4
September 2007
- Jerini Regains Commercialization Rights to Icatibant for the Treatment of Hereditary Angioedema in North America
- 31
August 2007 - FDA licenses Acambis' ACAM2000T vaccine
for protection against Smallpox
- 28
August 2007
- Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
- 23
August 2007 - EUSA Pharma acquires Innocoll’s antibiotic and pain control products and European sales and marketing infrastructure
- 20
August 2007 - ProStrakan announces commencement of recruitment in pivotal US Trials for Fortigel (Tostran) and Cellegesic (Rectogesic)
- 20
August 2007 - Onyx - Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
- 17
August 2007 - CSL - Uptake of Free Cervical Cancer Vaccines Exceeds Expectations
- 16
August 2007 - Jerini Receives EMEA Filing Acceptance of its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema
- 7
August 2007
- Lux Granted Fast Track Designation by FDA for LX211 for The Treatment of Uveitis
- 7
August 2007
- Archemix and Isis Pharmaceuticals Form Strategic Alliance for Aptamer Drug Discovery and Development
- 31
July 2007
- EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences’ LX 211 for The Treatment of Uveitis
- 30
July 2007 - ev3 Receives CE Mark Approval for the Axium™ Detachable
Coil System
- 26
July 2007 - Shire - 2007 guidance upgraded as revenue growth accelerates
- 23
July 2007 - ev3 and FoxHollow to Merge in Transaction Creating Global Leader in Endovascular Device Market
- 16
July 2007 - Affymax(R) Announces Phase 3 Development Plan for Hematide(TM)
- 11
July 2007 - Allergy Therapeutics - FDA Clinical Update
- 10
July 2007 - Noven acquires JDS Pharmaceuticals , expanding business model & broadening product pipeline
- 5
July 2007 - ProStrakan Reports Strong Revenue Growth in Pre-Close Trading Update
- 28
June 2007 - Santarus and Victory Pharma Announce
Co-Promotion Agreement for NAPRELAN Prescription Products
- 22
June 2007 - Alexion's Soliris(TM) Granted Marketing
Approval In Europe For Treatment Of All Patients With PNH
- 20
June 2007 - Noven & Shire to Develop New Transdermal
Patch For ADHD
- 11
June 2007 - Archemix and Merck KGaA Sign Strategic
Alliance
- 11
June 2007 - Archemix and Takeda to Enter into
Collaboration for Discovery and Development of Aptamer Therapeutics
- 7
June 2007 - Dynogen Reports Positive Results in
Phase 1B GERD Study
- 31
May 2007 - Progenics and Wyeth Announce FDA
Has Accepted For Filing the New Drug Application for Subcutaneous
Methylnaltrexone
- 31
May 2007 - Paion Topline Results Of Phase III Study In Acute
Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between
Desmoteplase And Placebo
- 25
May 2007 - Micromet and Nycomed Enter Into Exclusive
Worldwide Collaboration to Develop and Commercialize Anti-GM-CSF
Antibodies for the Treatment of Inflammatory and Autoimmune Diseases
- 17
May 2007 - Acambis – ACAM2000 receives positive recommendations from Advisory
Committee
- 1
May 2007 - Acusphere Announces Positive Results
from Pivotal Phase 3 Clinical Trial of Imagify (TM)
- 23
April 2007 - AstraZeneca to acquire MedImmune for
$58 per share in a fully recommended, all-cash transaction with
a total enterprise value of $15.2 billion
- 16
April 2007 - FDA Accepts GPC Biotech's Satraplatin
NDA for Filing and Grants Priority Review Status
- 30
March 2007 - Progenics and Wyeth Announce Submission
of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone
for the Treatment of Opioid-Induced Constipation in Patients
Receiving Palliative Care
- 16
March 2007 - FDA Approves Alexion's Soliris(TM) for
All Patients with PNH
- 1
March 2007 - EUSA Pharma raises $175m for both
the acquisition of OPi SA and further development of the Company
- 23
February 2007 - Shire announces FDA Approval
of VYVANSE™ as
a Novel Treatment for ADHD
- 20th
February 2007 - Shire agrees to acquire new river to gain full
control of Vyvanse™, its future flagship product for ADHD
- 13
February 2007 - Dynogen Reports Positive Results
in Phase 2 IBS-c Study
- 8
February 2007 - Gilead and Achillion Announce
Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue
GS 9132 (ACH-806) Development
- 17
January 2007 - Archemix and Merck KGaA to Collaborate
on Aptamer-Based Cancer Therapeutics
- 9
January 2007 - Archemix Announces Collaboration
with Pfizer to Discover Aptamer Therapeutics
Click
here for IBT Portfolio Company News 2006
Back to Top
^
|
